Numab Therapeutics is a pioneering brand that specializes in designing and developing powerful therapeutics for the treatment of severe diseases. With their innovative plug-and-play platform, they have revolutionized the discovery process, reducing the random nature of it and yielding predictably effective multispecific biotherapeutics for chronic inflammation and cancer. The team at Numab Therapeutics consists of highly skilled professionals, including their Chief Executive Officer, David Urech, who has a wealth of experience in antibody discovery.

Their Chief Business Officer, Oliver Middendorp, brings his expertise in intellectual property and alliance management. They also have a Chief Medical Officer, Chief Operating Officer, Chief Financial Officer, General Counsel, Senior VP Research and Preclinical Development, VP Discovery, Senior VP Technology and CMC, and a VP Clinical Operations & Regulatory Affairs. Each member of the team contributes their unique skill set to drive the success of Numab Therapeutics.

With a focus on delivering innovative and effective therapies, Numab Therapeutics is at the forefront of the biopharmaceutical industry. They continuously strive to make a positive impact on patients' lives by pushing the boundaries of scientific advancements